2-methoxy-ethoxymethoxy chloride

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methoxy-ethoxymethoxy chloride
• 英文别名: MEM chloride；Methoxyethoxylmethoxyl chloride；2-methoxyethoxymethyl hypochlorite
• 化学式: C₄H₉ClO₃
• 分子量: 140.567
• InChiKey: BSUDJHSINDEMCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methoxy-ethoxymethoxy chloride 、 2,4-二羟基苯甲醛 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以81%的产率得到2-Hydroxy-4-<(2-methoxyethoxy)methoxy>benzaldehyd
  参考文献：
  名称：

  Inhibitors of DNA polymerase β: Activity and mechanism

  摘要：

  Bioassay-guided fractionation of extracts prepared from Couepia polyandra and Edgeworthia gardneri resulted in the isolation of the DNA polymerase beta (pol beta) inhibitors oleanolic acid (1), edgeworin (2), betulinic acid (3), and stigmasterol (4). Study of these pol b inhibitors revealed that three of them inhibited both the lyase and polymerase activities of DNA polymerase beta, while stigmasterol inhibited only the lyase activity. Further investigation indicated that the four inhibitors had substantially different effects on the DNA-pol beta binary complex that is believed to be an obligatory intermediate in the lyase reaction. It was found that the inhibitors potentiated the inhibitory action of the anticancer drug bleomycin in cultured A549 cells, without any influence on the expression of pol beta in the cells. The results of the unscheduled DNA synthesis assay support the thesis that the potentiation of bleomycin cytotoxicity by DNA pol beta inhibitors was a result of an inhibition of DNA repair synthesis. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.071

文献信息

• Substituted sulfonic acid
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US06034093A1

  公开（公告）日：2000-03-07

  The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

  公式I的化合物表现出有用的药理活性，因此被纳入药物组合物中，并用于治疗患有某些医学疾病的患者。更具体地说，它们是凝血因子Xa活性的抑制剂。本发明涉及公式I的化合物、含有公式I化合物的组合物，以及它们的用途，用于治疗患有或受到可通过给予凝血因子Xa活性抑制剂而得到改善的生理状况的患者。
• Breast cancer resistance protein (bcrp) inhibitor
  申请人：Yamazaki Ryuta

  公开号：US20060128636A1

  公开（公告）日：2006-06-15

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH 3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR 1 (R 1 is hydrogen or C1-C4 alkyl), —O(CH 2 ) n COOR 2 (n=1−7: R 2 is hydrogen or C1-C4 alkyl), —OOCCH 2 CH 2 COOR 3 (R 3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH) 2 ) or a salt thereof, a sulfate group (i.e., —OSO 3 H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  本发明提供了一种抑制BCRP的药物。一种含有以下式（1）所表示的二苯乙烯腈衍生物作为活性成分的乳腺癌耐药蛋白抑制剂：[其中，8个R分别表示氢原子、羟基、硝基、氨基、乙酰氨基（—NHCOCH3基）、氰基（—CN基）、甲酰基（—CHO基）、—COOR1（R1为氢或C1-C4烷基）、—O（CH2）nCOOR2（n = 1-7：R2为氢或C1-C4烷基）、—OOCCH2CH2COOR3（R3为氢、C1-C4烷基、（Z）-2-（3,4-二甲氧基苯基）-3-（4-羟基苯基）-丙烯腈或葡萄糖基）、C1-C8烷氧基、C1-C4烷基、卤原子、C1-C4烷氧基C1-C4烷氧基C1-C4烷氧基、C2-C8酰氧基、C2-C8卤代酰氧基、亚甲二氧基基团、三氟甲基基团、磷酸酯基团（即—OP（O）（OH）2）或其盐、硫酸酯基团（即—OSO3H）或其盐、葡萄糖基或其盐、葡萄糖基的磷酸酯或酯的盐、葡萄糖基的硫酸酯或酯的盐，或者是它的酯或盐。
• Breast cancer resistance protein (BCRP) inhibitor
  申请人：Kabushiki Kaisha Yakult Honsha

  公开号：US07371773B2

  公开（公告）日：2008-05-13

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1−7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., —OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  该发明提供了一种抑制BCRP的药物。一种含有以下式（1）所表示的二苯丙烯腈衍生物作为活性成分的乳腺癌耐药蛋白抑制剂：[其中，8个R，它们相同或不同，分别表示氢原子，羟基，硝基，氨基，乙酰氨基（—NHCOCH3基），氰基（—CN基），甲酰基（—CHO基），—COOR1（R1为氢或C1-C4烷基），—O（CH2）nCOOR2（n = 1-7：R2为氢或C1-C4烷基），—OOCCH2CH2COOR3（R3为氢，C1-C4烷基，（Z）-2-（3,4-二甲氧基苯基）-3-（4-羟基苯基）-丙烯腈或甘露糖基），C1-C8烷氧基，C1-C4烷基，卤原子，C1-C4烷氧基C1-C4烷氧基C1-C4烷氧基，C2-C8酰氧基，C2-C8卤代酰氧基，亚甲二氧基基团，三氟甲基基团，磷酸盐基（即—OP（O）（OH）2）或其盐，硫酸盐基（即—OSO3H）或其盐，甘露糖基或其盐，甘露糖基的磷酸酯或其盐，甘露糖基的硫酸酯或其盐，或哌啶基哌啶羧酰氧基]，其酯或其盐。
• Oligonucleotide Probes
  申请人：Barbarella Giovanna

  公开号：US20090137789A1

  公开（公告）日：2009-05-28

  Fluorescent oligonucleotide probe having a general formula (I), wherein Onu represents an oligonucleotide residue, Thio n represents a fluorescent oligothiophene containing n thiophenic rings, n being an integer lower than 8, L representing a binder conceived to maintain Thio n mobile in relation to Onu in a manner so that Thio n can perform its fluorescent action correctly, and Onu can perform its hybridization action. (I)=Onu-L-Thio n .

  具有一般式（I）的荧光寡核苷酸探针，其中Onu代表寡核苷酸残基，Thion代表含有n个噻吩环的荧光寡噻吩，n为小于8的整数，L代表绑定剂，旨在以一种使Thion能够正确发挥其荧光作用的方式将Thion与Onu相关联，而Onu可以发挥其杂交作用。（I）= Onu-L-Thion。
• WO2007/5491
  申请人：——

  公开号：——

  公开（公告）日：——